HilleVax, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert M. Hershberg
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 75 State Street Boston MA United States of America 02109
- IPO Date
- Apr 29, 2022
- CIK
- 0001888012
- Website
- hillevax.com
- Similar Companies
- Business
- HilleVax, Inc. (Nasdaq: HLVX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate targeting norovirus, the leading cause of acute gastroenteritis worldwide, which affects children, older adults, and individuals with weakened immune systems. HIL-214 is designed to provide broad protection against multiple norovirus strains through its multivalent approach mimicking the virus structure without genetic material. HilleVax was founded in 2020 and is headquartered in Boston, Massachusetts. The company operates primarily in the United States with ongoing clinical trials conducted globally, including sites in the US, Europe, and Asia, targeting markets in developed regions with high incidence of norovirus outbreaks such as healthcare facilities, cruise ships, and long-term care settings. In recent developments, HilleVax completed enrollment in its Phase 2b NEST-IN1 clinical trial for HIL-214 in early 2024, with topline data expected in the second half of 2024, marking a key milestone toward pivotal trials; additionally, the company strengthened its manufacturing capabilities through a partnership with Dynavax Technologies for antigen supply and reported positive interim safety data from pediatric trials in 2024.
HILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX
Shareholder Alert: The Ademi Firm Investigates Whether HilleVax, Inc. Is Obtaining a Fair Price for Its Public Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of HilleVax, Inc. (NASDAQ: HLVX)
HilleVax Reports Second Quarter 2025 Financial Results
HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
Shareholder Alert: The Ademi Firm investigates whether HilleVax, Inc. is obtaining a Fair Price for its Public Shareholders
HLVX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of HilleVax, Inc. Is Fair to Shareholders
Kosmos Energy Posts Downbeat Q2 Results, Joins HilleVax And Other Big Stocks Moving Lower In Monday's Pre-Market Session
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
HilleVax (HLVX) Upgraded to Strong Buy: What Does It Mean for the Stock?
HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
Frazier Life Sciences Appoints Aditya Kohli to Partner
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress
What Makes HilleVax (HLVX) a New Buy Stock
HilleVax, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by HilleVax (HLVX)
Levi & Korsinsky Investigates Possible Securities Fraud Violations by HilleVax, Inc. (HLVX)
Investors who lost money on HilleVax, Inc. should contact Levi & Korsinsky about an ongoing investigation - HLVX